Flupirtine - Synthetic Biologics

Drug Profile

Flupirtine - Synthetic Biologics

Alternative Names: Effirma

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator ASTA Medica
  • Developer Meda; NNRI; Synthetic Biologics
  • Class Aminopyridines; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action KCNQ potassium channel agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Fibromyalgia
  • Discontinued Retinitis pigmentosa

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 22 Feb 2013 US FDA approves a phase II, proof-of-concept trial for flupirtine in Fibromyalgia
  • 16 Feb 2012 Adeona Pharmaceuticals is now called Synthetic Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top